Janux Shares Are Trading Higher After It Announced Doses Selected for Its Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose.
Janux Shares Are Trading Higher After It Announced Doses Selected for Its Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose.
Janux股票在宣佈爲其10億擴展試驗選擇的劑量後交易上漲,支持這一選擇的有利療效和安全性特點在1a期劑量中得到了觀察。
Janux Shares Are Trading Higher After It Announced Doses Selected for Its Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose.
在1a期劑量中觀察到的令人鼓舞的療效和安全性的支持下,Janux宣佈了其10期擴展試驗的選定劑量,股價走高。